| Stage | ABT | % of rev | BSX | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $13.0B | 100.00% | $5.1B | 100.00% | ABT ×2.53 |
| Gross profit | $7.4B | 56.75% | $3.4B | 66.72% | BSX +10.0pp |
| Operating income | $1.4B | 10.44% | $828M | 16.12% | BSX +5.7pp |
| Pre-tax income | $1.2B | 9.46% | $733M | 14.27% | BSX +4.8pp |
| Net income | $920M | 7.07% | $580M | 11.29% | BSX +4.2pp |
| Stage | ABT | BSX | Gap · A − B |
|---|---|---|---|
| Revenue | $13.0B100.00% | $5.1B100.00% | ABT ×2.53 |
| Gross profit | 56.75%$7.4B | 66.72%$3.4B | BSX +10.0pp |
| Operating income | 10.44%$1.4B | 16.12%$828M | BSX +5.7pp |
| Pre-tax income | 9.46%$1.2B | 14.27%$733M | BSX +4.8pp |
| Net income |
| 7.07%$920M |
| 11.29%$580M |
| BSX +4.2pp |
ABT · ITGR 10-KFeb 23 '26
“During 2025, three of our customers, Abbott Laboratories, Boston Scientific and Medtronic were each in excess of 10% of total sales and collectively accounted for 49% of our total sales.”
BSX · ITGR 10-KFeb 23 '26
“During 2025, three of our customers, Abbott Laboratories, Boston Scientific and Medtronic were each in excess of 10% of total sales and collectively accounted for 49% of our total sales.”